CRISPR interference and activation of the microRNA-3662-HBP1 axis control progression of triple-negative breast cancer

Yi, Baozhu; Wang, Shuaibin; Wang, Xinran; Liu, Zhichao; Zhang, Chao; Li, Ming; Gao, Song; Wei, Shi; Bae, Sejong; Stringer-Reasor, Erica; Liu, Runhua

doi:10.1038/s41388-021-02089-6

Cited by 15 publications

(24 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Wnt signalling plays an important role in embryonic development, whose deregulation leads to the initiation and progression of human malignancy via regulation of target gene expression. Canonical Wnt/β-catenin signalling is a potential therapeutic target in malignancies, such as NSCLC and triplenegative breast cancer [23]. Malignant tumour cells acquire invasive-associated phenotypes via regulation of the Wnt pathway.…”

Section: Discussionmentioning

confidence: 99%

Role of MicroRNA-214 in Dishevelled1-Modulated β-catenin Signalling in Non-Small Cell Lung Cancer Progression

Zhao¹,

Wang²,

Wu³

et al. 2023

J. Cancer

View full text Add to dashboard Cite

Background:The mortality of patients with non-small cell lung cancer (NSCLC) is rather high. This is largely because of the lack of specific targets and understanding of the molecular mechanism for early diagnosis. Dishevelled (Dvl) dysregulation leads to malignant progression. We confirmed that Dvl1 expression is associated with a poor prognosis of patients with NSCLC. However, how Dvl1 transmits signals through the Wnt/β-catenin pathway remains unknown. Methods:In this study, the expression levels of Dvl1 and β-catenin in resected NSCLC samples were immunohistochemically analysed. Dvl1 cDNA and small interfering RNA against β-catenin were transfected into NSCLC cells, and their effects on canonical Wnt signalling and biological behaviour of NSCLC cells were analysed. Using bioinformatics analyses, an interaction between microRNA (miR)-214 and β-catenin was identified; miR-214 expression was determined in NSCLC tissues using quantitative real-time polymerase chain reaction. An exogenous miR-214 (mimic) was used to analyse the biological behaviour of NSCLC cells and the effect of Dvl1 on canonical Wnt activation.Results: Dvl1 overexpression in NSCLC tissues as well as Dvl1 and β-catenin nuclear coexpression were significantly associated with poor prognosis of NSCLC (P < 0.05). Additionally, Dvl1 promoted Wnt/β-catenin signalling to enhance the malignant phenotype of NSCLC cells. Moreover, miR-214 directly targeted the 3′ untranslated region of β-catenin to inhibit the activation of canonical Wnt signalling induced by Dvl1. Conclusions: Our results suggest that Dvl1 is a potential therapeutic target for NSCLC and that miR-214 plays an inhibitory role in Dvl1-mediated activation of Wnt/β-catenin signalling in NSCLC cells, which could affect NSCLC progression.

show abstract

Section: Discussionmentioning

confidence: 99%

Role of MicroRNA-214 in Dishevelled1-Modulated β-catenin Signalling in Non-Small Cell Lung Cancer Progression

Zhao¹,

Wang²,

Wu³

et al. 2023

J. Cancer

View full text Add to dashboard Cite

show abstract

“…Proliferation and cell cycle progression of these malignant tumors and their therapy response are also modulated by CRISPR/Cas9 system. [121][122][123][124][125][126][127][128] Noteworthy, delivery of CRISPR/ Cas9 system can pave the way for improving its efficacy in gene expression regulation, which is the focus of the current section. the purpose of breast cancer therapy.…”

Section: Crispr/cas9 Systemmentioning

confidence: 99%

(Nano)platforms in breast cancer therapy: Drug/gene delivery, advanced nanocarriers and immunotherapy

Ashrafizadeh

Zarrabi

Bigham

et al. 2023

Medicinal Research Reviews

View full text Add to dashboard Cite

Breast cancer is the most malignant tumor in women, and there is no absolute cure for it. Although treatment modalities including surgery, chemotherapy, and radiotherapy are utilized for breast cancer, it is still a life‐threatening disease for humans. Nanomedicine has provided a new opportunity in breast cancer treatment, which is the focus of the current study. The nanocarriers deliver chemotherapeutic agents and natural products, both of which increase cytotoxicity against breast tumor cells and prevent the development of drug resistance. The efficacy of gene therapy is boosted by nanoparticles and the delivery of CRISPR/Cas9, Noncoding RNAs, and RNAi, promoting their potential for gene expression regulation. The drug and gene codelivery by nanoparticles can exert a synergistic impact on breast tumors and enhance cellular uptake via endocytosis. Nanostructures are able to induce photothermal and photodynamic therapy for breast tumor ablation via cell death induction. The nanoparticles can provide tumor microenvironment remodeling and repolarization of macrophages for antitumor immunity. The stimuli‐responsive nanocarriers, including pH‐, redox‐, and light‐sensitive, can mediate targeted suppression of breast tumors. Besides, nanoparticles can provide a diagnosis of breast cancer and detect biomarkers. Various kinds of nanoparticles have been employed for breast cancer therapy, including carbon‐, lipid‐, polymeric‐ and metal‐based nanostructures, which are different in terms of biocompatibility and delivery efficiency.

show abstract

“…In macrophage cell lines, CRISPR-mediated indel formation in miR-155 reduced pro-inflammatory cytokine expression in vitro, creating an avenue for treating the autoimmune disease rheumatoid arthritis 103 . miRNA targeting has also been extensively studied in cancer 104 ; various approaches have been shown to lead to reductions in cancer cell proliferation 105 – 107 , inhibition of metastasis 105 , 106 and death of cancer cells 108 in preclinical studies.…”

Section: Targeting the Non-coding Genomementioning

confidence: 99%

“…For example, in settings in which a lncRNA silences a paternal allele, leaving only a mutant maternal allele, the generation of indels in the lncRNA can disrupt its function, leading to the therapeutic expression of the wild-type paternal allele 91,92 . f | To increase the concentration of a therapeutically relevant gene, Cas proteins can be used to form indels in the microRNA (miRNA) or the 3′ untranslated region, leading to a reduction in miRNA binding and amelioration of the resulting RNA interference [101][102][103][104][105][106][107][108] .…”

Section: Long Non-coding Rnasmentioning

confidence: 99%

Advances in CRISPR therapeutics

et al. 2022

View full text Add to dashboard Cite

The clustered regularly interspaced short palindromic repeats (CRISPR) renaissance was catalysed by the discovery that RNA-guided prokaryotic CRISPR-associated (Cas) proteins can create targeted double-strand breaks in mammalian genomes. This finding led to the development of CRISPR systems that harness natural DNA repair mechanisms to repair deficient genes more easily and precisely than ever before. CRISPR has been used to knock out harmful mutant genes and to fix errors in coding sequences to rescue disease phenotypes in preclinical studies and in several clinical trials. However, most genetic disorders result from combinations of mutations, deletions and duplications in the coding and non-coding regions of the genome and therefore require sophisticated genome engineering strategies beyond simple gene knockout. To overcome this limitation, the toolbox of natural and engineered CRISPR–Cas systems has been dramatically expanded to include diverse tools that function in human cells for precise genome editing and epigenome engineering. The application of CRISPR technology to edit the non-coding genome, modulate gene regulation, make precise genetic changes and target infectious diseases has the potential to lead to curative therapies for many previously untreatable diseases.

show abstract

CRISPR interference and activation of the microRNA-3662-HBP1 axis control progression of triple-negative breast cancer

Cited by 15 publications

References 50 publications

Role of MicroRNA-214 in Dishevelled1-Modulated β-catenin Signalling in Non-Small Cell Lung Cancer Progression

Role of MicroRNA-214 in Dishevelled1-Modulated β-catenin Signalling in Non-Small Cell Lung Cancer Progression

(Nano)platforms in breast cancer therapy: Drug/gene delivery, advanced nanocarriers and immunotherapy

Advances in CRISPR therapeutics

Contact Info

Product

Resources

About